Infliximab (anti-TNF-α) reverses the steatosis and the expression of the proinflammatory markers (TNF-α, IL6, IL-1B) and improves insulin signal trasduction in a model of steatosis in rats [20]. This evidence concerns the gene TNF and steatosis.